




Harnessing the Body's Natural Drain to Cure Disease



Lymphatic System: Vast but Underappreciated

- Manage fluid balance

- Clears cellular waste

- Key player in immunity

Lymphatic Dysfunction Can Impact Every Organ System



Glaucoma,
Uveitis,
Retinopathy



Dementia,
Alzheimer's
Parkinson's



Primary
lymphedema,
vascular
abnormalities



Lupus, MS,
Sjogren's



IBD, Celiac,
Diabetes




Heart Failure,
Hypertension

No FDA Approved Therapies That Improve Lymphatic Function

Master Regulator of the Lymphatic System

- **VEGF-C** activates VEGFR3
- **VEGFR3**: Master regulator of lymphatic system
- **Absence** of either one results in **lymphatic dysfunction** and underdeveloped vessels




What does lymphatic activation mean?

Increased Lymphatic Pumping



New Lymphatic Vessel Growth




VEGF-C also activates VEGFR2


- **VEGF-C** also activates VEGFR2

- VEGFR2 is responsible for **vasodilation and angiogenesis**

- When the body upregulates lymphangiogenesis it also upregulates angiogenesis




Challenge: Coupled with angiogenesis




Rho Bio's Solution

Lymphatic activation without angiogenesis



Highly Specific VEGFR3 Binding



LS-VEGF-C has comparable binding to VEGFR3 as WT VEGF-C



Strong IP


Covering mutations at a dozen positions



Advanced Product

Ready to enter cell line development

Highly Potent VEGFR3 Activation




LS-VEGF-C just as potently activates VEGFR3 as WT-VEGF-C




Extensive animal work

Treated numerous species (mice, rabbits, minipigs, NHPs). Up to 28 days. No toxicity observed.

Glaucoma: Back of the eye disease with only front of the eye treatments






Decrease
Pressure



Improve
Neuroprotection

Activating lymphatics to protect the optic nerve

LS-VEGF-C Injection



Decrease
Pressure



Improve
Neuroprotection

Glaucoma Treatment Paradigm

Eyedrops




1 to 4


*Combinations of
eyedrops*



LS-VEGF-C
Injection



Device




Operation

220K

Glaucoma Procedures per Year
US Claims Data 2021

A new solution for an expanded glaucoma population



Team built to drive ophthalmology to the clinic with foundations in lymphatic biology



Jennifer Beecham
President, COO



Michael Ehrlich, MD
Strategic Advisor



Craig Hackett, PhD
CMC Advisor



Gary Novack, PhD
Regulatory and Non-Clinical Advisor



Namrata Saroj, OD
Clinical Advisor



Scientific Founders



Eric Song, MD, PhD
Discovered Optic Nerve Lymphatics



Aaron Ring, MD, PhD
Serial Entrepreneur, Protein Engineer



Jony Kipnis, PhD
Discovered Meningeal Lymphatics



Akiko Iwasaki, PhD
Immunobiologist, BoD Roche and Genentech



Advanced Preclinical Program
(\$300K Non-Dilutive Funding through Yale)



- DME
- Induced Glaucoma
- Genetic Glaucoma
- Lymphedema
- Alzheimer's (Ongoing)



- Normal Tensive Glaucoma
- Toxicity (*Ocular and Systemic*)



- Normal Tensive Glaucoma
- Toxicity (*Ocular and Systemic*)



- Generated human protein library
- Selected best binder/activator
- Improved stability
- Filed IP

Rho Bio Development Plan

